Plexin B2 (PLXNB2) is a transmembrane receptor belonging to the plexin family, which plays critical roles in cell-cell signaling by interacting with semaphorins. It is involved in regulating diverse biological processes, including axon guidance, cell migration, immune response, and tissue development. Structurally, PLXNB2 contains a large extracellular domain for ligand binding, a transmembrane region, and an intracellular domain that mediates downstream signaling through interactions with Rho GTPases and other cytoskeletal regulators. Dysregulation of PLXNB2 has been implicated in pathological conditions such as cancer progression, neurodevelopmental disorders, and vascular abnormalities. For instance, elevated PLXNB2 expression correlates with tumor invasiveness in glioblastoma and breast cancer, likely by promoting metastatic signaling pathways.
PLXNB2 antibodies are essential tools for studying its expression, localization, and functional mechanisms. These antibodies are typically developed against specific epitopes within the extracellular or intracellular domains of PLXNB2 and are validated for applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Commercially available PLXNB2 antibodies often undergo rigorous specificity testing, including knockout validation, to ensure accurate detection. Researchers utilize these antibodies to explore PLXNB2's role in disease models, its interaction with ligands like Sema4C, and its crosstalk with oncogenic pathways such as ErbB2-mediated signaling. Additionally, PLXNB2-targeting antibodies hold therapeutic potential, particularly in blocking pro-invasive signaling in cancers or modulating immune responses in inflammatory diseases.